Product Pipeline

Therapeutics
Pre-clin
Phase 1
Phase 2
Phase 3
NDA/BLA
Phase
Ryplazim®
Congenital Deficiency
Learn More
Fezagepras (PBI-4050)
Additional Multiple Ascending Dose (MAD) Study
Fezagepras (PBI-4050)
Lung
Learn More
Fezagepras (PBI-4050)
Liver
Fezagepras (PBI-4050)
Kidney
Fezagepras (PBI-4050)
Alström Syndrome
Learn More
Selective GPR84 Antagonist
Fibrosis
Learn More
Selective OXER1 Antagonist
Respiratory/GI
Learn More